Audenz is an inactivated cell-based influenza vaccine that contains MF59, a proprietary adjuvant.
Patients with Gaucher disease do not appear to be at increased risk for SARS-CoV-2 infection, according to findings presented at the 17th Annual WORLDSymposium.